Terns Pharmaceuticals, Inc.

    Terns Pharmaceuticals, Inc.

    NNASDAQ:TERN
    52.95
    USD
    0.00
    (0.00%)
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    0.04
    - -
    - -
    - -
    - -
    - -
    Basic EPS, GAAP
    -0.74
    -2.86
    -1.29
    -2.21
    -1.67
    -1.27
    -1.12
    - -
    -1.05
    Free Cash Flow per Basic Share
    -0.76
    -2.8
    -1.34
    -1.86
    -1.37
    -0.95
    -0.88
    - -
    -0.9
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -0.97
    -3.83
    -5.81
    -8.02
    -6.73
    -4.67
    -5.3
    - -
    -5.65
    Tangible Book Value per Share
    -0.95
    -3.79
    -5.17
    7.06
    7.69
    3.58
    4.35
    - -
    10.99
    Basic Weighted Avg Shares
    24
    24
    23
    23
    36
    71
    80
    - -
    92
    Sales/Revenue/Turnover
    - -
    - -
    - -
    1
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    -4,986
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    - -
    - -
    - -
    1
    1
    1
    1
    1
    1
    Net Income, GAAP
    -18
    -69
    -40
    -50
    -60
    -90
    -89
    -96
    -96
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    -5,015.8
    - -
    - -
    - -
    - -
    - -
    Working Capital
    86
    17
    68
    160
    277
    255
    346
    1,008
    1,008
    LT Debt
    - -
    - -
    - -
    - -
    1
    - -
    1
    - -
    - -
    Total Equity
    72
    4
    69
    160
    277
    255
    346
    1,007
    1,007
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    1
    1
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    87
    88
    112
    Market Capitalization
    328
    687
    3,700

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    Total Current Assets
    319
    300
    1,024
    Cash, Cash Equivalents & STI
    315
    296
    1,019
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    13
    15
    16
    Payables & Accruals
    9
    10
    9
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    85.03%
    191.01%
    Free Cash Flow
    - -
    22.72%
    17.3%
    Net Income, GAAP
    - -
    20.36%
    8.28%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.31
    -0.25
    -0.42
    - -
    -1.27
    2024
    -0.3
    -0.31
    -0.28
    -0.24
    -1.12
    2025
    -0.26
    -0.26
    -0.27
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Address
    Similar Companies
    Business

    Company News

    • Tern shares surge as it ups stakes in AI health services company Talking Medicines

    • Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

    • Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss

    • Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?

    • Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

    • Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

    • Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?

    • Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN

    • Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?

    • Why Terns Pharmaceuticals Stock Rocked the Market in March

    • Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

    • Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

    • Shareholder Alert: Ademi LLP investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

    • Capricorn Fund Managers Ltd Takes $6.12 Million Position in Terns Pharmaceuticals, Inc. $TERN

    • Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

    • Here Are Tuesday’s Top Wall Street Analyst Research Calls: Arista Networks, Block, Colgate-Palmolive, Digital Realty, Emerson Electric, MiniMed, Shake Shack, and More

    • Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More

    • Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up

    • E. Ohman J or Asset Management AB Sells 81,208 Shares of Terns Pharmaceuticals, Inc. $TERN

    • Terns Pharmaceuticals (NASDAQ:TERN) Sets New 12-Month High – Here’s Why